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Background: The aim of this study was to compare the efficacy of two neoadjuvant chemotherapies (FLEEOX and
XELOX) with different routes of administration for unresectable gastric cancer.
Methods: A total of 85 patients with unresectable gastric cancer hospitalized from January 2007 to December 2009
received neoadjuvant chemotherapy. The FLEEOX group (48 patients) received the FLEEOX regimen(fluorouracil,
leucovorin, epirubicin, epotoside, and oxaliplatin), which combined arterial with venous administration for one or
two cycles, while the XELOX group (37 patients) received XELOX (capecitabine plus oxaliplatin) via venous
administration for two to four cycles. The clinical response and overall survival of the two groups were compared.
Results: In the FLEEOX group, the clinical response rate (RR) of chemotherapy was 85.4% (41 of 48 patients) and
the median survival time was 25 months. The 1-year and 2-year disease-free survival (DFS) rates were 85.4% and
45.8%, respectively. In the XELOX group, the clinical RR was 59.5% and the median survival time was 9 months,
while the 1-year and 2-year survival rates were 35.2% and 8.3%, respectively. The clinical RR, the R0 resection rate,
the median survival time, and the 1-year and 2-year DFS rates were significantly better (P < 0.05) in the FLEEOX
group than in the XELOX group. In addition, there were no significant differences in the rates of toxic and adverse
reactions or post-operative complications between the two groups.
Conclusions: For patients with a preoperative diagnosis of unresectable gastric cancer, the efficacy of the FLEEOX
regimen, which combines arterial with venous administration, was better than that of the XELOX regimen, using
venous administration only. This combination of arterial and venous administration could be useful for improving
the efficacy of neoadjuvant chemotherapy for gastric cancer.
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Gastric cancer is the second most common cancer in the
world. Nearly 41% of the global gastric cancer cases
occur in China [1], and the vast majority of cases in
China present as advanced gastric cancer. The efficacy of
surgical treatment for advanced gastric cancer is not high
[2], and efforts are being made to improve treatments for
gastric cancer. In recent years, a number of clinical stud-
ies (including the Medical Research Council Adjuvant* Correspondence: drguolili2012@yahoo.com.cn
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shown that preoperative chemotherapy can improve the
outcomes in advanced gastric cancer [3], which opens up
a new avenue for treating this cancer. At present, the
approaches and methods of post-operative adjuvant
chemotherapy of gastric cancer are generally used for
preoperative chemotherapy as well.
Several chemotherapy regimens are available. The
XELOX regimen has the advantages of easy administra-
tion and two effective drugs that have been used in neoad-
juvant chemotherapy for advanced gastric cancer [4,5],
namely, oxaliplatin and capecitabine [6-8]. Based on the
FLEP (5-FU, leucovorin, etoposide, and cisplatin) regimen.
After the exploring of the preoperative chemotherapyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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December 2002 [9,10] we obtained a very satisfactory effi-
cacy rate with the FLEEOX regimen for unresectable,
advanced gastric cancer. The FLEEOX regimen is a com-
bination of venous and regional chemotherapy, compris-
ing continuous intravenous infusion 5-fluorouracil and
leucovorin, followed by intra-aterial infusion of epirubicin,
etoposide, and oxaliplatin. In previous studies, the initial
radiological response rate (RR) with this regimen was
about 80% [11].
In this study, we compared venous administration of
XELOX versus combined arterial and venous adminis-
tration of FLEEOX, and assessed the short-term efficacy
of both groups.Methods
Ethics approval
The study was approved by Ethics committee of Jinling
Hospital and informed consent was obtained from all
patients.
The study enrolled patients with unresectable,
advanced gastric cancer who were hospitalized from
January 2007 to December 2009. Cancers meeting the
following criteria were diagnosed as unresectable gastric
cancer:1) strongly suspicious for stage III or IV metasta-
sis of lymph nodes by enhanced CT examination; 2)
tumor infiltration and encompassment of major blood
vessels (for example, hepatic artery, celiac artery, and
portal vein); 3) distant metastasis (for example, liver me-
tastasis). The inclusion criteria were:age35 to75 years;
Eastern Cooperative Oncology Group (ECOG) score of 0
to 2; no previous history of curative or palliative surgery,
radiotherapy or chemotherapy; no serious cardiovascular,
liver, or kidney disease; and acceptance of chemotherapy
and interventional chemotherapy. The exclusion criteria
were: pregnancy or breast-feeding; presence of peritoneal
seeding or distant metastasis except in the liver; presence
of other malignant tumors; history of curative or pallia-
tive surgery, radio therapy, or chemotherapy; history of
upper gastrointestinal bleeding, perforation, obstructive
jaundice, severe infections, or other serious complica-
tions; history of any serious or uncontrollable venous dis-
eases; or sensitivity to any of the chemotherapy drugs.
In total, 85 patients (62 men, 23 women, 61 ± 13 years,
range 35 to 75 years) were enrolled in the study. The
diagnosis of gastric cancer was confirmed by histopatho-
logical examination of an endoscopic biopsy sample. The
clinical staging of all cases were confirmed by CT and
endoscopic ultrasonography before treatment. The rela-
tionship between the tumor and major blood vessels or
organs in its proximity, and the extent of lymph-node
metastasis were assessed by multi-slice spiral CT and
endoscopic ultrasonography.Preoperative chemotherapy
The selected cases were randomly divided into two groups
to receive the appropriate preoperative chemotherapy regi-
mens: 48 patients received the FLEEOX regimen, which
combined arterial with venous administration, and 37
patients received the XELOX regimen, which was given by
venous administration only.
The FLEEOX regimen consisted of a slow intravenous
infusion of 5-fluorouracil(5-FU) 370 mg/m2over 5 days
and an intravenous infusion of calcium folinate 200 mg/
m2over 5 days. Following this, oxaliplatin 120 mg/m2,
epirubicin 30 mg/m2, and etoposide 70 mg/m2 were
injected into the tumor site on days 6 and 20. Patients
received one or two cycles of this regimen; for those
patients receiving two cycles, the second cycle was admi-
nistered after an interval of 5 weeks. The arterial admin-
istration was performed using the Seldinger method.
After intubation of the celiac artery, a catheter was
inserted into the blood supply of the tumor depending
on the tumor site; for example, the catheter was inserted
into the left gastric artery for cancer of the upper and
central stomach, and through the hepatic and gastroduo-
denal arteries into the right gastroepiploic artery for can-
cer of the lower part of the stomach. First, half the drug
volume was injected into the artery supplying the tumor,
then the remaining drug was injected into the celiac ar-
tery, except for patients with accompanying liver metas-
tases, for whom the second half of the drug was injected
into the metastatic focus in the liver. Lipiodol
embolization was also performed for the latter patients.
The XELOX regimen comprised intravenous infusion
of oxaliplatin 130 mg/m2over 2 hours on day 1, followed
by capecitabine 1000 mg/ m2 orally twice daily for
2 weeks. This cycle was repeated once every 3 weeks,
and patients were given two to four cycles.
Evaluation criteria for efficacy and adverse events
The efficacy was evaluated by CT after three cycles of
intervention treatment in the FLEEOX (combined arter-
ial and venous administration), and three cycles in the
XELOX (intravenous administration) group. Patients
whose tumors were deemed resectable would have their
chemotherapy stopped and surgery performed. Patients
whose tumors were considered unresectable would con-
tinue chemotherapy for two cycles (FLEEOX group) or
four cycles (XELOX group), after which the efficacy was
again evaluated by CT. At this point, any patients with
resectable tumors would undergo surgery. The study
would be stopped for any patients whose tumors were
not resectable.
The efficacy was evaluated by two radiologists with
using the Response Evaluation Criteria In Solid Tumors
(RECIST) criteria [12]. Tumors were evaluated as follows:
complete disappearance of the tumor was considered to







Patients, n 48 37
Age, years) 38 to 73 38 to 75
Gender, n (%)
Male 35 (72.9) 27 (73.0) 1.00
Female 13 (27.1) 10 (27.0)
ECOG1
0 29 (60.4) 21 (56.8) 0.94
1 13 (27.1) 11 (29.7)
2 6 (12.5) 5 (13.5)
Site of lesion
Cardia 19 (39.6) 17 (45.9) 0.82
Gastric body 15 (31.3) 11 (29.7)
Gastric antrum 14 (21.1) 9 (24.4)
Degree of differentiation
Severe 3 (6.3) 2 (5.4) 0.57
Moderate 13 (27.1) 14 (37.8)
Mild 32 (66.6) 21 (56.8)
Pre-treatment stage, n (%)
III 20 (41.7) 21 (56.8) 0.191
IV 28 (58.3) 16 (43.2)
Reasons for non-resection
Tumor and metastatic lymph
nodes with encompassment
of major blood vessels
44 (91.7) 35 (94.6) 0.74
Liver metastasis 1 (2.1) 1 (2.7)
NO.16 group of lymph nodes 3 (6.3) 1 (2.7)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; FLEEOX,
fluorouracil, leucovorin, epirubicin, epotoside and oxaliplatin; XELOX.
capecitabine plus oxaliplatin.
1Significant.
Table 2 Response to treatment of chemotherapy of the
patients in both groups
Response rates FLEEOX, n = 48 XELOX,n = 37
CR, n (%) 6 (12.5) 1 (2.7)
PR, n (%) 35 (72.9) 20 (54.1)
SD, n (%) 5 (10.4) 12 (32.4)
PD, n (%) 2 (4.2) 4 (10.8)
Abbreviations: CR, complete response; FLEEOX, fluorouracil, leucovorin,
epirubicin, epotoside and oxaliplatin; PD, progressive disease; PR, partial
response; SD, stable disease; XELOX. capecitabine plus oxaliplatin.
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in tumor size to be partial response (PR), and an increase
of more than 20% in tumor size as progressive disease
(PD), neither sufficient shrinkage to qualify for partial re-
sponse nor sufficient increase to qualify for progressive
disease was considered stable disease (SD). Clinical RR
was calculated as: (CR + PR)measurable number of
cases) × 100%. Surgery (mainly D2 gastrectomy) was car-
ried out within 2 weeks of the end of preoperative
chemotherapy for patients with resectable gastric cancer.
D3 gastrectomy was performed for patients with tumors
andN3 lymph-node metastasis.
Adverse events
Patients were closely monitored for liver and kidney
function, bone-marrow hematopoiesis, gastrointestinal
reactions, and related adverse events during the treat-
ment. Toxic reactions were evaluated using the National
Cancer Institute Common Toxicity Criteria (version 3.0)
and compared between two groups.
Follow-up
After chemotherapy, patients attended a clinical follow-up
review every 3 months, which included physical examin-
ation, routine blood investigations, assessment of liver
and kidney function, tumor markers, abdominal CT, and
chest X-ray. Gastroscopy was performed once every year.
Statistical analysis
The primary objective indicators were clinical objective
RR (CR + PR), 1-year and 2-year disease-free survival
(DFS) rates, and median survival time. The survival rate
was calculated by the Kaplan-Meier method. Secondary
indicators were R0 resection rate, characteristics of the
resected specimen, and toxic reactions. Overall survival
(OS) time was recorded from first chemotherapy to
death or the last follow-up visit. Comparison between
the two groups was performed using the χ² test. Data
were analyzed using the SPSS statistical software (ver-
sion 17.0; SPSS Inc., Chicago, IL, USA). P < 0.05 was
considered significant.
Results
The age and sex distribution and physical condition of
the patients were similar in both groups (median age of
the patients was 62 years in the FLEEOX group and
59 years in the XELOX group; Table 1). Both groups
were also comparable with regard to tumor site, degree
of tumor differentiation, and stage of tumors (P > 0.05)
(Table 1).
Response rate of chemotherapy
Of the forty-eight patients in the FLEEOX group, six
patients were rated as having CR, thirty-five as PR, fiveas SD, and two as PD; the clinical RR was 85.4%. For the
thirty-seven patients in the XELOX group, the figures
were one, twenty, twelve and four, respectively, and the
clinical RR was 59.5%. There was a significant difference
in RR (P < 0.02) between the two groups (Table 2).
Table 3 Rates of surgery in both groups
FLEEOX, n = 48 XELOX, n = 37
R0, n (%) 36 (75.0) 17 (45.9)
R1, n (%) 4 (8.3) 1 (2.7)
R2, n (%) 1 (2.1) 3 (8.1)
Inoperable, n (%) 7 (14.5) 16 (43.3)
Refused surgery, n (%) 1 (2.1) 0 (0)
FLEEOX, fluorouracil, leucovorin, epirubicin, epotoside and oxaliplatin; XELOX.
capecitabine plus oxaliplatin.
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In the FLEEOX group, the tumors were evaluated as re-
sectable in nine patients after the second treatment cycle
and in thirty-two patients after the third cycle. Of the
remaining seven patients, six were evaluated as invalid or
having disease progression, and one patient refused sur-
gery. Of the forty-one patients approved for surgery, thirty-
eight underwent D2 gastrectomy and three underwent
D3 gastrectomy. The gastrectomy was a distal subtotal
gastrectomy in twenty patients and a total gastrectomy in
twenty-one patients. Thirty-six of the patients underwent
R0 resection (thus theR0 resection rate was 75%; 36/48),
while four patients underwent R1 resection and one under-
went R2 resection.
The thirty-seven patients in the XELOX group
received two (n = 5), three (n = 11) or four (n = 21)
cycles of chemotherapy. Sixteen patients were evaluated
as invalid or having disease progression, and thus could
not undergo surgery. The remaining twenty-one patients
who were approved for surgery all underwent D2 gas-
trectomy, with twelve operations being distal subtotal
gastrectomy and nine being total gastrectomy. Seventeen
patients underwent R0 resection (R0 resection rate ofFigure 1 Post-operative specimen. The mucous membrane shows scar-l
gastroepiploic artery, but the gastric mucosa outside the chemotherapy de45.9% (17/37)), while one patient underwent R1 resec-
tion and three underwent R2 resection.
There was a significant difference between the two
groups in the R0 resection rate (P < 0.001)(Table 3).Changes in surgical specimens
Upon intra-operative and post-operative observation of
the primary tumors and metastatic lymph nodes, atro-
phic changes were found in 27 primary tumors in
FLEEOX group, which occurred as caseous necrosis and
scar-like changes in the corresponding lymph nodes.
Necrosis of the gastric mucosa was visible in the peri-
tumoral arterial administration area in 17 patients. Se-
vere cases showed obvious scar-like changes (Figure 1).
Atrophic changes were found in 13 primary tumors in
the XELOX group, which produced caseous necrosis on
the corresponding lymph nodes, but the gastric mucosa
in the peri-tumoral area was normal in all patients.Post-operative complications
Between the two groups, there were 76 patients who
received D2 gastrectomy. There were no deaths due to
the surgery. There were seven (16.3%) instances of post-
operative complications in the FLEEOX group (two cases
of intestinal obstruction and two cases of abdominal in-
fection, and one case each of anastomotic leakage, pneu-
monia, and wound infection), and six (18.1%) in the
XELOX group (two cases of abdominal infection, and
one case each of intestinal obstruction, anastomotic leak-
age, pneumonia, and wound infection). There was no
significant difference in the incidence rate of postopera-
tive complication of the patients in two groups (P >0.05),
and all patients recovered with conservative treatment.ike changes after chemotherapy in areassupplied by the right
livery area was normal.
Table 4 Comparison of toxic reactions of chemotherapy
in both groups
Toxic reactions FLEEOX XELOX
Hematologic
Anemia,n(%)
Grade 0, 1 or 2 45 (94.8) 37(100)
Grade 3 or 4 3 (5.2) 0 (0)
Leukopenia,n(%)
Grade 0, 1 or 2 46 (95.8) 36 (97.3)
Grade 3 or 4 2 (4.2) 1(2.7)
Neutropenia,n(%)
Grade 0, 1 or 2 48 (100) 37 (100)
Grade 3 or 4 0 (0) 0(0)
Thrombocytopenia,n(%)
Grade 0, 1 or 2 45 (94.8) 35 (94.6)
Grade 3 or 4 3 (5.3) 2 (5.4)
Abnormal AST,n(%)
Grade 0, 1 or 2 44 (91.7) 37 (100)
Grade 3 or 4 4 (8.3) 0 (0)
Abnormal ALT,n(%)
Grade 0, 1 or 2 44 (91.7) 37 (100)
Grade 3 or 4 4 (8.3) 0 (0)
Nonhematologic
Nausea,n(%)
Grade 0, 1 or 2 43 (89.6) 36 (97.3)
Grade 3 or 4 5 (10.4) 1 (2.7)
Vomiting,n(%)
Grade 0, 1 or 2 45 (94.8) 35 (94.6)
Grade 3 or 4 3 (5.2) 2 (5.4)
Neurotoxicity,n(%)
Grade 0, 1 or 2 48 (89.6) 36 (97.3)
Grade 3 or 4 0 1 (2.7)
HFSR ,n(%)
Grade 0, 1 or 2 45 (94.8) 37 (100)
Grade 3 or 4 3 (5.2) 0 (0)
Renaldysfunction,n(%)
Grade 0, 1 or 2 48 (89.6) 37 (100)
Grade 3 or 4 0 0 (0)
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In total, there were 207 completed cycles of chemother-
apy for the two groups. No treatment termination or
death occurred as a result of toxic reactions. During the
chemotherapy, there were different degrees of toxic and
adverse reactions in the two groups. The reactions were
mainly myelosuppression, liver dysfunction, and gastro-
intestinal reactions. With regard to bone-marrow sup-
pression, the levels of hemoglobin, white blood cells,
and platelets decreased in some patients within both
group. The most common symptom was leukopenia
(n = 30; 62.5%) in the FLEEOX group and anemia (n =
24; 64.9%) in the XELOX group. Alanine aminotransfer-
ase (ALT) and aspartate aminotransferase (AST), which
are markers of liver injury, increased in nine (18.8%) and
eleven patients (22.9%), respectively, in the FLEEOX
group, and in nine (24.3%) and eight patients (21.6%) in
the XELOX group. The commonest digestive-tract reac-
tions in both groups were varying degrees of nausea and
vomiting, with 38 patients (79.2%) in the FLEEOX group
reporting nausea,22(57.9%) patients vomiting, and 19
patients (51.4%) in the XELOX group reporting vomit-
ing,25(67.7%) patients nausea. Toxic neurological reac-
tion occurred in 21 patients (56.8%) in the XELOX, but
in only 11 patients (22.9%) in the FLEEOX group. For
most patients, there were only minor changes in renal
function, with no marked change in levels of creatinine
or urea nitrogen before and after chemotherapy in either
groups. There was no significant difference in the num-
ber of toxic reactions between the two groups (P >0.05)
(Table 4).
Survival and disease-free survival
The survival time of the 85 patients was calculated. The
median survival time was 25 and 9 months in the
FLEEOX group and the XELOX group, respectively,
which was significantly different (P < 0.001) (Figure 2).
The 1-year and 2-year DFS rates were 85.4% and 45.8%,
respectively, in the FLEEOX group, and 35.2% and 8.3%,
respectively, in the XELOX group. The 1-year and 2-
year DFS rates were 83.3% (40/48) and 33.3% (16/48) re-
spectively in the FLEEOX group, with the number of
recurrences in R0 patients being two and eighteen in the
first year and second years, respectively. For the XELOX
group, the 1-year and 2-year DFS rates were 33.3% (16/
48) and 5.4%(2/37)respectively, and the number of
recurrences in R0 patients were three and twelve in the
first and second years, respectively. There was a signifi-
cant difference in DFS rates between the two groups
(P < 0.05) (Figure 3).
Discussion
The result of surgical treatment of advanced gastric can-
cer is often less than ideal [13]. The prognosis ofunresectable gastric cancer with severe lymph-node me-
tastasis or distant metastasis is poor, with a survival time
of only 6 to 12 months [14-17]. Many clinical studies
have shown that chemotherapy can downstage the
tumor, eliminate micrometastases, and make some unre-
sectable gastric cancers resectable, thereby prolonging
the survival time of patients [18-21]. Therefore, pre-
operative chemotherapy of gastric cancer has become an
important part of cancer treatment, and identifying ef-
fective chemotherapy regimens has become the focus of
clinical research into gastric cancer.
Figure 2 Survivalin both groups. The median survival time was 25 months in the FLEEOX group and 9 months in the XELOX group.
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stead of capecitabine and oxaliplatin which have the
similar efficacy but lower toxicity of chemotherapy
[22,23] for XELOX regimen, making XELOX regimen
easier to accept in clinical practice, which is the more
commonly used method of venous administration at
present. Park et al. showed that the clinical RR to the
XELOX regimen to the patients with advanced gastric
cancer was 63%, and median survival time wasFigure 3 Disease-free survival curves for both groups.11.9 months [24]. In this study, we obtained similar
results, with a clinical RR of 59.5%, and a median sur-
vival time of 9 months.
The development of the EAP regimen (etoposide,
doxorubicin, and cisplatin) greatly improved the efficacy
of preoperative chemotherapy for gastric cancer greatly,
but this regimen is highly toxic. Some authors reported
the use of arterial infusion for this regiment, but it did
not significantly reduce toxicity. Nakajima et al., used
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intravenous infusion of 5-FU and leucovorin. The FLEP
regimen, which combines arterial with venous adminis-
tration, is a development of the EAP (etoposide, doxo-
rubicin and cisplatin) regimen, with excellent efficacy
[18]. Drawn from the experience of Nakajima et al., the
FLEEOX regimen uses oxaliplatin , which is less toxic
than cisplatin, and thus reduce the toxicity of arterial ad-
ministration. The adding of epirubicin helps to form the
EEOX regiment, which uses arterial administration, and
is similar to the EAP regimen. 5-FU is a time-dependent
drug, while epirubicin and oxaliplatin are concentration-
dependent drugs, thus a slow intravenous infusion of
5-FU can maintain its effective time, while local arteiral
infusion of EEOX can maintain the concentrations. The
pharmacological effect of two different types of drug can
be enhanced by the different routes of administration,
which can take the clinical RR up to 85.4%. In the
current study, the R0 resection rate and survival rate of
the FLEEOX group were substantially compared with
the XELOX group, but the toxicity reactions did not in-
crease significantly.
We also found that a considerable number of the
resected specimens in the FLEEOX group, showed evi-
dence of necrosis and scarring in the gastric mucosa
within the region of administration, probably due to high
concentrations of drug. This shows that the FLEEOX
regimen using local arterial administration has a very in-
tense effect on local tissues. This type of damage did not
occur in the XELOX group, probably because it used
venous administration only and the drug concentrations
were lower than FLEEOX.
The rationale behind drug combinations is to use sev-
eral drugs acting on different parts of the cell cycle to
improve the efficacy, produce a synergistic beneficial ef-
fect, and avoid deleterious combinations of the toxic
effects of the drugs. After years of research, the currently
available chemotherapy drugs have been played the syn-
ergistic effect adequately The current regimens have
reached the limit of the synergistic effect [8,25-28], and
thus, without the development of more effective drugs,
it is difficult to greatly improve the efficacy of the avail-
able chemotherapeutic regimens for gastric cancer.
Thus, in the current study, we investigate a preoperative
chemotherapy regimen that combined arterial and ven-
ous administration, that is, using an intravenous slow in-
fusion of a time-dependent drug to optimize its effective
time, along with local arterial administration of a
concentration-dependent drug to maintain its local con-
centration. The different routes of administration can
enhance the pharmacological effect of the drugs by
exploiting their different actions. By using an optimal
combination of administration routes, it should be pos-
sible not only to enhance the pharmacological effect butalso to use combinations of five drugs, which could
greatly improve the efficacy of the regimens.
Conclusions
Our results show that for patients with a preoperative
diagnosis of unresectable gastric cancer, the efficacy of
the FLEEOX regimen, which combines arterial with ven-
ous administration, was better than that of the XELOX
regimen, using venous administration only. The FLEEOX
regimen is a safe and promising regimen for preopera-
tively treatment of advanced gastric cancer.
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